An update on gene therapy for lysosomal storage disorders

Area of Science:

• Genetics
• Molecular Biology
• Biotechnology

Background:

• Lysosomal Storage Disorders (LSDs) are inherited genetic conditions caused by enzyme deficiencies.
• Current treatments for LSDs are often costly, burdensome, and may lack sufficient efficacy.
• LSDs are well-suited for gene therapy due to the potential for enzyme secretion and cross-correction.

Purpose of the Study:

• To review recent advancements in gene therapy for LSDs.
• To discuss the advantages and disadvantages of various gene therapy vectors and approaches.
• To highlight emerging strategies and future directions in the field.

Main Methods:

• Focus on lentiviral and adeno-associated virus vectors in clinical trials for LSDs.
• Emphasis on ex vivo hematopoietic stem cell-directed gene therapy, systemic/liver-directed gene therapy, and brain-directed gene therapy.
• Discussion of next-generation gene therapy approaches to address challenges.

Main Results:

• Pre-clinical studies demonstrate the efficacy and safety of gene therapy for LSDs.
• Clinical trials show promising results, indicating gene therapy is a viable treatment option.
• Various gene therapy strategies are advancing towards clinical application.

Conclusions:

• Gene therapy holds significant potential for long-term correction of LSDs.
• Despite being in its early stages, gene therapy for LSDs shows considerable promise.
• Continued research and development are crucial for realizing the full potential of gene therapy for LSD patients.